11 results
The first objective is measuring striatal D2 receptor binding before and after dopamine depletion with AMPT in the UHR population compared to healthy controls, and investigate whether dopaminergic dysregulation is present prior to transition to…
1. How functions the dopaminergic neurotransmission in adult patients with VCFS who are functioning on an intellectual level of moderate to severe impairment (IQ < 55) by a) a strong cognitive decline or b) a premorbid level of functioning.2…
Main goal is to gain more insight in the role of dopaminergic neurotransmission in rewards, motivation and the attribution of salience in the etiology of psychosis. Primary question is whether a change in blood oxygation level dependent (BOLD) fMRI…
To compare the efficacy and safety of methotrexate versus azathioprine treatment in adult patients with chronic severe AD.
With this study we want to identify the common aetiology and neurobiology of EFD, by employing pharmacological and genetic imaging in three neuropsychiatric disorders. We want to identify an underlying functional and structural model for EFD,…
To evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF subjects with impaired glucose tolerance (IGT) or CF related diabetes (CFRD)
To evaluate the long-term safety and tolerability of elexacaftor(ELX)/tezacaftor (TEZ)/ivacaftor (IVA)
To evaluate the efficacy and pharmacodynamics (PD) of ELX/TEZ/IVA
To evaluate the efficacy of VX-121/TEZ/D-IVA in CF subjects who are homozygous forF508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, orhave at least 1 other TCR CFTR mutation and no F508del mutation
The aim of this study is to investigate the efficacy of subcutaneous IFX in the treatment of moderate to severe Crohn*s disease with and without concomitant immunosuppression, as measured by the proportion of patients in corticosteroid-free clinical…
To compare the effectiveness of weekly subcutaneously administered MTX for maintaining relapse-free sustained steroid/EN-free 1-year remission compared with:- daily oral AZA/6MP in low risk paediatric CD- subcutaneously administered adalimumab in…